NCT00364988已完成不适用
Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy
Shanghai Jiao Tong University School of Medicine0 个研究点目标入组 60 人开始时间: 2005年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 主要终点
- Renal function
研究概览
简要总结
Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 32 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
- •2h plasma glucose level of 7.5-13 mmol/L
- •serum creatinine values between 190 and 660umol/L
- •Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is >150mg
- •Informed consent
排除标准
- •Type1 diabetes or nondiabetic renal disease
- •abnormal liver function
- •heart dysfunction
结局指标
主要结局
Renal function
时间窗: 12 month
fasting glucose, HbA 1c , Scr, 24-hour urinary protein excretion, and endogenous creatinine clearance (Ccr)
次要结局
未报告次要终点
研究者
Hui Min Jin
Chief,department of Nephrology,shanghai No.3 people's hospital
Shanghai Jiao Tong University School of Medicine
相似试验
已完成
不适用
Can the use of the PPAR-gamma agonist rosiglitazon reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in HIV-associated lipodystrophy syndrome?HIV+ patients, with lipodystrophy (based on fat distribution disturbances), not using d4T nor a protease inhibitor.NL-OMON25981Academic medical centre, Dept of endocrinology and metabolism, F5-170, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands15
已完成
4 期
The Practical Evidence of Antidiabetic Combination Therapy in KoreaType 2 Diabetes MellitusNCT02231021Kun-Ho Yoon216
已完成
4 期
A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLDNon-alcoholic Fatty Liver DiseaseType 2 DiabetesNCT02285205Yonsei University38
已完成
2 期
A Phase II Study of Pioglitazone for Patients With Cancer of the PancreasCancer of the PancreasNCT01838317University of Texas Southwestern Medical Center14
已完成
2 期
Pioglitazone as an Adjunct for Moderate to Severe Depressive DisorderMajor Depressive DisorderNCT01109030Tehran University of Medical Sciences50